These signalling molecules – a myriad of which are called cytokines – control inflammation and immunity. Cytokines that are produced according to the GMP cytokines market are manufactured to a high level of quality control for safety and effectiveness. It is an accelerated market given advancements in biotechnology, the rise in demand for biologics, and the rise in autoimmune diseases and cancer.

Market Overview

The global GMP cytokines market is divided by product type (interleukins, interferons, tumour necrosis factors, growth factors), application (cancer treatment, autoimmune disease treatment, regenerative medicine), and end-user (pharmaceutical companies, biotech companies, research labs).

Key Market Trends

• Innovations in Biotechnology: Advances in recombinant DNA technology and cell culture methods made it possible to manufacture quality GMP cytokines at scale.
• Increase in Cases of Chronic Diseases: The rise in the number of chronic conditions (Cancer, Autoimmune disease, Infectious diseases etc) is creating a demand for cytokine-based therapies.
• Increased Demand for Immunotherapy: Immunotherapy which uses the body’s immune system to combat illness is now considered a promising therapeutic approach that drives the demand for GMP cytokines.
• Rising R&D Expenditures: Major investments in biotech and pharmaceutical research are promoting new cytokine therapies.
• Restrictive Regulatory Conditions: Manufacturing and sale of GMP cytokines requires strict regulatory conditions (GMP and GLP).

Market Size and Forecast

The GMP Cytokines Market size is projected to reach US$ 350.2 million by 2031 from US$ 128.7 million in 2023. The market is expected to register a CAGR of 9.7% in 2023–2031.

Frequently Asked Questions

Why is the growth of the GMP cytokines market?

• Advancements in biotechnology
• Rising prevalence of chronic diseases
• Growing focus on immunotherapy
• Increasing R&D investments
• Stringent regulatory environment

What will be the major regions that are driving the GMP cytokines market?

North America and Europe are the mature markets for GMP cytokines but Asia-Pacific is rapidly becoming a market due to rising healthcare costs and R&D investment.